two studies of the drug in relapsing forms of MS – GEMINI 1 and 2 – were unable to show any improvement with tolebrutinib compared to Sanofi's current oral MS therapy Aubagio (teriflunomide ...
However, two other trials in relapsing forms of MS – GEMINI 1 and 2 – were unable to show an improvement over Sanofi's older therapy Aubagio (teriflunomide). The company said at the time it ...
The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback